U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.
U.S. President Donald Trump, Eli Lilly (LLY.N) and Novo Nordisk (NOVOb.CO) signed a deal in November to slash the prices of ...
Some Medicare enrollees may soon be able to access super-popular drugs for obesity under a voluntary model program, the Centers for Medicare and Medicaid Services announced Tuesday. Eligible ...
The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration (FDA) approving ...
Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.
This new pill contains the same active ingredient as injectable Wegovy and Ozempic, semaglutide. It is the first GLP-1 pill ...
The FDA has approved the first-ever Wegovy pill for weight loss, with the oral GLP-1 offering a 16.6% average weight ...
Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four weeks. Ozempic-- a once-weekly injectable formulation of semaglutide -- is ...
Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "Competition is leading to lower prices, better value, and ...
Weight gain is one of the most worrying side effects for young people taking certain medications for bipolar disorder. These medicines, known as second‑generation antipsychotics, are very effective at ...
CLEVELAND — Northeast Ohio residents will have access to comprehensive free medical and dental care later this month when MedWish Medworks hosts its annual two-day clinic at the Huntington Convention ...
Results from the largest and longest study of its kind found the drug metformin can help manage weight gain in overweight or obese youth taking medication to treat bipolar disorder and should be ...